1)American Psychiatric Association:Diagnostic and Statistical Manual of Mental Disorders, Fifth ed. (DSM-5). American Psychiatric Publishing, Washington D.C., 2013(日本精神神経学会日本語版用語監修,髙橋三郎,大野裕監訳:DSM-5精神疾患の診断・統計マニュアル.医学書院,2014)
2)World Health Organization:The ICD-10 Classification of Mental and Behavioural Disorders:Clinical Descriptions and Diagnostic Guidelines. WHO, Geneva, 1992(融道男,中根允文,小見山実他監訳:ICD-10精神および行動の障害—臨床記述と診断ガイドライン新訂版.医学書院,2005)
3)小枝達也:神経学的検査,身体的一般検査,齊藤万比古,渡辺京太編:注意欠陥/多動性障害の診断・治療ガイドライン改訂版.pp56-58,じほう,2006
4)木村記子,岡田俊:ADHDとてんかんの併存例における診断と治療.児童青年精神医学とその近接領域51:148-163,2010
5)Dupaul GJ, Thomas JP, Anastopoulos AD, et al:ADHD rating Scale-Ⅳ:Checklist, Norms, and Clinical Interpretation, New York, The Guilford Press, 1998(市川宏伸,田中康雄監,坂本律訳:診断・対応のためのADHD評価スケール—ADHD-RS(DSM準拠)チェックリスト,標準値とその臨床的解釈.明石書店,2008)
6)後藤太郎,山下裕史朗,宇佐美政英,他:小児の生活機能評価のためのツール「子どもの日常生活チェックリストQCD」の臨床応用の可能性.小児科臨床64:99-106,2011
7)Conners CK原著,田中康夫監訳,坂本律訳:Conners 3日本語版マニュアル.金子書房,2011
8)Spencer T, Wilens T, Biederman J, et al:A double-blind, crossover comparison of methylphenidate and placebo in adults with childhood-onset attention-deficit hyperactivity disorder. Arch Gen Psychiatry 52:434-443, 1995
9)Bymaster FP, Katner JS, Nelson DL, et al:Atomoxetine increases extracellular levels of norepinephrine and dopamine in prefrontal cortex of rat:a potential mechanism for efficacy in attention deficit/hyperactivity disorder. Neuropsychopharmacology 27:699-711, 2002
10)ADHDの診断・治療指針に関わる研究会,齊藤万比古編:注意欠如・多動症—ADHD—の診断・治療ガイドライン 第4版.じほう,2016
11)Faraone SV:Using meta-analysis to compare the efficacy of medications for attention-deficit/hyperactivity disorder in youths. PT 34:678-694, 2009
12)Faraone SV, Buitelaar J:Comparing the efficacy of stimulants for ADHD in children and adolescents using meta-analysis. Eur Child Adolesc Psychiatry 19:353-364, 2010
13)NICE:Attention deficit hyperactivity disorder:diagnosis and management. 2018 http://www.nice.org.uk/guidance/ng87(2022年3月1日閲覧)
14)Bangs ME, Tauscher-Wisniewski S, Polzer J, et al:Meta-analysis of suicide-related behavior events in patients treated with atomoxetine. J Am Acad Child Adolesc Psychiatry 47:209-218, 2008
15)Ichikawa H, Miyajima T, Yamashita Y, et al:Long-term study of lisdexamfetamine dimesylate in Japanese children and adolescents with attention-deficit/hyperactivity disorder. Neuropsychopharmacol Rep 40:52-62, 2020
16)Reale L, Bartoli B, Cartabia M, et al:Comorbidity prevalence and treatment outcome in children and adolescents with ADHD. Eur Child Adolesc Psychiatry 26:1443-1457, 2017
17)Mannuzza S, Klein RG, Bonagura N, et al:Hyperactive boys almost grown up. V. Replication of psychiatric status. Arch Gen Psychiatry 48:77-83, 1991
18)Offord DR, Boyle MH, Szatmari P, et al:Six-month prevalence of disorder and rates of service utilization. Arch Gen Psychiatry 44:832-836, 1987
19)Lahey BB, Loeber R, Quay HC, et al:Oppositional defiant and conduct disorders:issues to be resolved for DSM-IV. J Am Acad Child Adolesc Psychiatry 31:539-546, 1992
20)Loeber R, Green SM, Lahey BB:Which boys will fare worse? Early predictors of the onset of conduct disorder in a six-year longitudinal study. J Am Acad Child Adolesc Psychiatry 34:499-509, 1995
21)Loeber R, Lahey BB, Thomas C:Diagnostic conundrum of oppositional defiant disorder and conduct disorder. J Abnorm Psychol 100:379-390, 1991
22)Konofal E, Lecendreux M, Cortese S:Sleep and ADHD. Sleep Med 11:652-658, 2010
23)Lee SH, Seo WS, Sung HM, et al:Effect of methylphenidate on sleep parameters in children with ADHD. Psychiatry Investig 9:384-390, 2012
24)Cortese S, Holtmann M, Banaschewski T, et al:Practitioner review:current best practice in the management of adverse events during treatment with ADHD medications in children and adolescents. J Child Psychol Psychiatry 54:227-246, 2013